Abstract:OBJECTIVE:To evaluate the therapeutic effect of mucosal tolerance on inflammatory bowel disease (IBD). METHODS:Forty-two SD rats underwent enema of 2, 4, 6-trinitro-benzene-sulfonic acid (TNBS) so as to establish models of experimental colitis and then divided into 7 equal groups: colitis group (without treatment), oral ovalbumin (OVA) group (undergoing gastric perfusion of OVA as inducing antigen), nasal OVA group (undergoing OVA nose dropping), oral OVA plus adjuvant group [undergoing gastric perfusion OVA with lipopolysaccharide (LPS) as adjuvant], nasal OVA plus adjuvant group, adjuvant control group, and blank control group (administrated with PBS orally). Another 6 rats were used as blank control group. All of the rats were executed 21 days after enema with their spleens taken out. Splenic lymphocytes were isolated and co-cultured with OVA for 96 h. MTT method was used to calculate the proliferation index so as to detect the mucosal tolerance. Macroscopical and histolopathological scores of colon were estimated so as to evaluate the therapeutic effects. RESULTS:Typical manifestations of colitis occurred 3-4 days after enema and persisted to the day 21 after enema. The macroscopical and histolopathological scores of colon of the colitis group (mean rank were 9.5 and 9.5) were both significantly higher than those of the normal control group (mean rank were 3.5 and 3.5 both P < 0.01). The splenic lymphocyte proliferation indexes of the oral OVA plus LPS, nasal OVA, and nasal OVA plus LPS groups were 0.11 +/- 0.05, 0.12 +/- 0.07, and 0.06 +/- 0.04 respectively, all significantly lower than that of the normal control group (0.30 +/- 0.13, all P < 0.05), however, without significant differences among these 3 groups (all P > 0.05). The splenic lymphocyte proliferation indexes of the oral OVA group was 0.25 +/- 0.10, not significantly different from that of the normal control group (P > 0.05). The macroscopical scores of the oral OVA plus LPS group, nasal OVA plus LPS group, and oral LPS alone group were 3.0 +/- 1.3, 2.0 +/- 0.6, and 4.3 +/- 1.0 respectively, all significantly lower than that of the colitis group (6.3 +/- 0.8, all P < 0.05); and the histological score of the oral OVA plus LPS group, nasal OVA plus LPS group, and oral LPS alone group were 3.0 +/- 1.1, 2.7 +/- 1.0, and 4.6 +/- 1.6 respectively, all significantly lower than that of the colitis group (7.5 +/- 1.0, all P < 0.05). The colonic score of the nasal OVA plus LPS group was most significantly decreased. CONCLUSION:Colitis interferes with the induction of oral tolerance, but not the induction of nasal tolerance. Both oral tolerance combined with adjuvant and nasal tolerance combined with adjuvant have therapeutic effects on experimental colitis. Oral adjuvant alone also has therapeutic effect on colitis, and the therapeutic effect of nasal tolerance combined with adjuvant is the best.

The Therapeutic Role of Oral Tolerance in Dextran Sulfate Sodium‐induced Colitis Via Th1–Th2 Balance and Γδ T Cells

The effect of oral tolerance on the roles of small intestinal intraepithelial lymphocytes in murine colitis induced by dextran sodium sulfate

Changes of CD8⁺ T Cells in Dextran Sulfate Sodium-Induced Colitis Mice Pretreated with Oral Immune Regulation.

The protective effect of oral colitis-derived proteins in a murine model of inflammatory bowel disease is associated with an increase in γδ T cells in large intestinal mucosa

The Protective Effect Of Oral Colitis-Derived Proteins In A Murine Model Of Inflammatory Bowel Disease Is Associated With An Increase In Gamma Delta T Cells In Large Intestinal Mucosa

Effects Of Appendectomy And Oral Tolerance On Dextran Sulfate Sodium Colitis

[Therapeutic effects of mucosal tolerance on inflammatory bowel disease: experiment with rats].

Therapeutic Effects of Mucosal Tolerance on Experimental Colitis in Rats

Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines

Gut microbiota modulation and anti-inflammatory properties of mixed lactobacilli in dextran sodium sulfate-induced colitis in mice

Isosteviol Attenuates DSS-induced Colitis by Maintaining Intestinal Barrier Function Through PDK1/AKT/NF-κB Signaling Pathway

Local Immune Compartments Are Related to the Severity of Dextran Sodium Sulphate Induced Colitis

Characterisation of Acute Murine Dextran Sodium Sulphate Colitis: Cytokine Profile and Dose Dependency

Preventive effects of TLR2 monoclonal antibodies and TLR4 monoclonal antibodies on the colonal mucosal inflammatory cytokines (IFN-γ,IL-4 and IL-17) expression in mice with DSS-induced acute ulcerative colitis

The role of CD19+ CD5+ CD1dhi B cells in dextran sulfact sodium (DSS)

Taurodeoxycholate ameliorates DSS-induced colitis in mice

The Role of CD19+CD5+CD1dhi B Cells in Dextran Sulfact Sodium (dss)induced Inflammatory Bowel Disease C57BL/6 Mouse Model

Alleviation Effects of Bifidobacterium animalis subsp. lactis XLTG11 on Dextran Sulfate Sodium-Induced Colitis in Mice

Dexmedetomidine alleviates intestinal barrier dysfunction and inflammatory response in mice via suppressing TLR4/MyD88/NF-κB signaling in an experimental model of ulcerative colitis

Protective effect of TSLP delivered at the gut mucosa level by recombinant lactic acid bacteria in DSS-induced colitis mouse model

Rectal Administration of Lipopolysaccharide and Ovalbumin Ameliorates Acute Murine Colitis